Cingulate (CING)

• Market cap: $13.2M
• 1 day: -4.97%
• 5 days: -6.68%
• 1 month: -16.36%
• 3 months: -13.78%
• 6 months: -32.78%
• Year to date: -28.82%
• 1 year: -75.41%
• 5 years: -99.66%
• 10 years: -99.66%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Employees: 13

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

78% more capital invested

Capital invested by funds: $252K [Q3] → $447K (+$196K) [Q4]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.53% more ownership

Funds ownership: 2.29% [Q3] → 2.83% (+0.53%) [Q4]

10% less funds holding

Funds holding: 10 [Q3] → 9 (-1) [Q4]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 231% upside
• Avg. target: $16 341% upside
• High target: $20 451% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 32% 1-year accuracy 109 / 342 met price target	451% upside $20	Buy Reiterated	6 Mar 2025
Roth MKM Boobalan Pachaiyappan 44% 1-year accuracy 4 / 9 met price target	231% upside $12	Buy Initiated	10 Jan 2025